• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[利加隆在非酒精性脂肪性肝病中的应用]

[Use of Legalon in non-alcoholic fatty liver disease].

作者信息

Buturova L I, Tsybizova T A, Kalinin A V

出版信息

Eksp Klin Gastroenterol. 2010(5):69-75.

PMID:20734480
Abstract

The article presents the current understanding of the etiology, pathogenesis of nonalcoholic fatty liver disease, its basic forms, risk factors, prevalence and clinical course. Shows the data of research on the effectiveness of purely herbal product Legalon, in the treatment of non-alcoholic fatty liver disease. The 2-month course of treatment was underwent in the research team, on that background there was noted positive dynamics: cropped asthenic syndrome, pain and heaviness in the right hypochondrium, dyspepsia. In assessing of the biochemical parameters was shown a significant decrease in serum transaminases, gamma-glyutamiltransaminazy level.

摘要

本文介绍了目前对非酒精性脂肪性肝病的病因、发病机制、基本形式、危险因素、患病率和临床病程的认识。展示了纯草药产品利加隆治疗非酒精性脂肪性肝病有效性的研究数据。研究团队进行了为期2个月的治疗疗程,在此期间观察到了积极的变化:虚弱综合征减轻、右季肋部疼痛和沉重感、消化不良。在评估生化参数时发现血清转氨酶、γ-谷氨酰转肽酶水平显著下降。

相似文献

1
[Use of Legalon in non-alcoholic fatty liver disease].[利加隆在非酒精性脂肪性肝病中的应用]
Eksp Klin Gastroenterol. 2010(5):69-75.
2
[Effect of carsil and legalon in treating chronic liver diseases].[凯西莱和利加隆治疗慢性肝病的疗效]
Vutr Boles. 1986;25(3):43-9.
3
[Study of clinical efficiency of essential phospholipids and silymarin combination in nonalcoholic and alcoholic steatohepatitis].
Eksp Klin Gastroenterol. 2011(7):64-9.
4
[Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C].[酒精性肝病和慢性丙型肝炎中的氧化应激与抗氧化防御]
Orv Hetil. 2000 Jul 23;141(30):1655-9.
5
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.非诺贝特治疗非酒精性脂肪性肝病的一项试点试验。
Dig Liver Dis. 2008 Mar;40(3):200-5. doi: 10.1016/j.dld.2007.10.002.
6
Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.综述文章:非酒精性脂肪性肝病和非酒精性脂肪性肝炎的当前管理
Aliment Pharmacol Ther. 2008 Jul;28(1):2-12. doi: 10.1111/j.1365-2036.2008.03710.x. Epub 2008 Apr 11.
7
[Liver-protective action of silymarin therapy in chronic alcoholic liver diseases].水飞蓟宾疗法对慢性酒精性肝病的肝脏保护作用
Orv Hetil. 1989 Dec 17;130(51):2723-7.
8
[Use of ursodeoxycholic acid combined with silymarin in the treatment of chronic ethyl-toxic hepatopathy].
Clin Ter. 2002 Sep-Oct;153(5):305-7.
9
Review article: Drug therapy for non-alcoholic fatty liver disease.综述文章:非酒精性脂肪性肝病的药物治疗
Aliment Pharmacol Ther. 2006 Jan 15;23(2):207-15. doi: 10.1111/j.1365-2036.2006.02751.x.
10
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.二甲双胍与维生素E或规定饮食治疗非酒精性脂肪性肝病的随机对照试验
Am J Gastroenterol. 2005 May;100(5):1082-90. doi: 10.1111/j.1572-0241.2005.41583.x.

引用本文的文献

1
Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病的调控网络、管理方法和新兴治疗方法。
Can J Gastroenterol Hepatol. 2022 Nov 8;2022:6799414. doi: 10.1155/2022/6799414. eCollection 2022.
2
Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review.水飞蓟素作为肝脏疾病的辅助治疗:叙述性综述。
Adv Ther. 2020 Apr;37(4):1279-1301. doi: 10.1007/s12325-020-01251-y. Epub 2020 Feb 17.
3
In vivo efficacy study of milk thistle extract (ETHIS-094™) in STAM™ model of nonalcoholic steatohepatitis.
水飞蓟提取物(ETHIS-094™)在非酒精性脂肪性肝炎的STAM™模型中的体内疗效研究。
Drugs R D. 2014 Dec;14(4):291-9. doi: 10.1007/s40268-014-0068-2.